Comparative Study of Pharmacopoeias in Japan, Europe, and the United States: Toward the Further Convergence of International Pharmacopoeial Standards.

European Pharmacopoeia Japanese Pharmacopoeia Pharmacopoeia Pharmacopoeial Discussion Group Pharmacopoeial Standards United States Pharmacopeia–National Formulary

Journal

Chemical & pharmaceutical bulletin
ISSN: 1347-5223
Titre abrégé: Chem Pharm Bull (Tokyo)
Pays: Japan
ID NLM: 0377775

Informations de publication

Date de publication:
2019
Historique:
entrez: 3 12 2019
pubmed: 4 12 2019
medline: 16 1 2020
Statut: ppublish

Résumé

A pharmacopoeia's core mission is to protect public health by creating and making available public standards to help ensure the quality of drugs. In recent years, pharmacopoeias around the world have harmonized their standards in the present context of globalized drug supply chains and markets. For example, the Pharmacopoeial Discussion Group has worked to harmonize excipient monographs and general chapters. In addition, the International Meeting of World Pharmacopoeias has been held by the WHO to discuss information exchange and international collaboration, among other topics. To contribute further to the protection of public health in the globalized drug market, we conducted a comparative study of the pharmacopoeias in Japan, Europe, and the United States. We aimed to examine current differences among the Japanese Pharmacopoeia, the European Pharmacopoeia, and the United States Pharmacopeia-National Formulary and to identify areas that require further collaboration among the three pharmacopoeias. In this study, we analyzed monographs and general chapters listed in the three pharmacopoeias. We identified the features of the monographs and general chapters listed in each pharmacopoeia, as well as differences across the pharmacopoeias. Moreover, on the basis of our findings, we suggest standards that require further collaboration among the pharmacopoeias in certain preferred areas. The comparison data produced by this study are expected to be used to develop strategies for future revisions of pharmacopoeias around the world.

Identifiants

pubmed: 31787657
doi: 10.1248/cpb.c19-00621
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1301-1313

Auteurs

Yujiro Kameyama (Y)

Division of Pharmacopoeia and Standards for Drugs, Office of Review Management, Pharmaceuticals and Medical Devices Agency.

Maki Matsuhama (M)

Division of Pharmacopoeia and Standards for Drugs, Office of Review Management, Pharmaceuticals and Medical Devices Agency.

Chie Mizumaru (C)

Division of Pharmacopoeia and Standards for Drugs, Office of Review Management, Pharmaceuticals and Medical Devices Agency.

Rieko Saito (R)

Division of Pharmacopoeia and Standards for Drugs, Office of Review Management, Pharmaceuticals and Medical Devices Agency.

Tsuyoshi Ando (T)

Division of Pharmacopoeia and Standards for Drugs, Office of Review Management, Pharmaceuticals and Medical Devices Agency.

Seiko Miyazaki (S)

Division of Social Pharmacy and Public Health, Showa Pharmaceutical University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH